Search
Human cytomegalovirus immune globulin
go.drugbank.com/drugs/DB13886ApprovedInvestigationalDuring the span of an individual's life, the virus may reactivate, resulting in repeated shedding and spread of the virus. … As a consequence, CMV disease is restricted to the immunocompromised or immunologically immature host, in which it can lead the devastating result of transplant rejection [A32498], [L2229].
Categories: Immunoglobulin G, Human Immunoglobulin GHexocyclium
go.drugbank.com/drugs/DB06787ApprovedHexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. … Proton pump inhibitors like [DB00338] and opiate anti-diarrheal agents like [DB00836] have largely replaced the use of anti-muscarinics in the treatment of gastric ulcers and diarrhea due to their more
Clocortolone
go.drugbank.com/drugs/DB00838ApprovedClocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp.
Cysteamine
go.drugbank.com/drugs/DB00847ApprovedInvestigational[A218721] Several preparations of cysteamine exist for the treatment of cystinosis manifestations, some in capsule form, and others in ophthalmic solution form. … [L15611] On August 25th 2020, the first ophthalmic solution for cystinosis requiring only 4 daily treatments was granted FDA approval.
Products: CYSTAGON ® 150 MG, CYSTAGON ® 50 MG CAPSULASGaretosmab
go.drugbank.com/drugs/DB16379ApprovedInvestigational[L63940] Garetosmab-grts was approved by the FDA on August 19, 2026 to reduce the number of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP. … [L63940] By preventing this aberrant signaling, it reduces the formation of new abnormal bone.[L63940] It is administered by intravenous infusion every four weeks.
Gentian violet cation
go.drugbank.com/drugs/DB00406ApprovedA dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.
Pozelimab
go.drugbank.com/drugs/DB15218ApprovedInvestigational[L47880] The pathophysiology of this disease is mainly attributed to the deficiency of the CD55 protein, which is the main regulator of the complement cascade.[A261105,A261110,A261115]. … CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US.
Finerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigational[A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449] … Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart
Products: KERENDİA 10 MG FİLM KAPLI TABLET, 98 ADET, KERENDİA 20 MG FİLM KAPLI TABLET, 98 ADETBitolterol
go.drugbank.com/drugs/DB00901ApprovedWithdrawnBitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.
Synonyms: 4-(2-(tert-butylamino)-1-hydroxyethyl)-o-phenylene di-p-toluate, 4-[2-(tert-butylamino)-1-hydroxyethyl]-o-phenylene di-p-toluateTriazolam
go.drugbank.com/drugs/DB00897ApprovedInvestigationalInternationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances. … Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S.
Products: TRIAZOLAM EG, Halcion 0,25 mg - Tabletten